Compound prescriptions; electronic prescriptions; effective date.
HB3367 amends Oklahoma’s controlled dangerous substances prescription law to require electronic prescribing in additional circumstances and to clarify when paper, oral, or facsimile prescriptions may still be used. The bill specifically addresses compound prescriptions, compounded infusion prescriptions, and prescriptions issued under approved research protocols, stating that electronic prescriptions may shall be utilized for those categories. It also preserves existing electronic-prescribing requirements for Schedule II through V controlled substances, while retaining a range of exceptions for emergencies, veterinary prescriptions, certain institutional settings, federal-property pharmacies, waiver/extension holders, short-duration supplies, and situations where a patient’s condition would be put at risk by delay.
The bill also keeps and restates the framework for official prescription forms, practitioner registration with the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control, recordkeeping, reporting of lost or stolen forms, and restrictions on refills and mailing controlled substances. It would continue to require documentation in the patient record when an exception to electronic prescribing is used, and it would require non-electronic prescriptions issued under certain exceptions to be on official forms approved by the Bureau. The act would take effect November 1, 2026.
HB3367 would amend 63 O.S. 2021, Section 2-309, which governs electronic prescriptions for controlled dangerous substances, by expanding and clarifying the electronic-prescribing mandate and the limited exceptions to it. Its practical effect would be to push more compound-related controlled substance prescriptions into electronic format, while preserving paper or oral prescribing only in specified circumstances and under documented exceptions. The bill would affect practitioners, pharmacists, hospitals, nursing facilities, hospice programs, veterinary prescribers, and the Bureau of Narcotics and Dangerous Drugs Control, but it does not create a new regulatory scheme so much as refine the existing one.
Based on the bill text and available context, the overall sentiment appears neutral to supportive of tighter prescription controls and modernization through electronic prescribing. There are no recorded committee transcripts or votes in the provided materials, so there is no evidence of organized opposition or formal debate in the available record. The bill’s structure suggests an effort to balance anti-diversion safeguards with practical exceptions for clinical and institutional settings.
The main points of potential contention are the expanded use of mandatory electronic prescribing for compound prescriptions and the administrative burden this may place on practitioners who prepare or dispense compounded medications. Another likely issue is the breadth of exceptions, especially for emergencies, technological failures, hospice care, federal facilities, and short-duration supplies, because those exceptions can affect how strictly the mandate is enforced. Pharmacists are explicitly relieved of any duty to verify whether a written, oral, or facsimile prescription falls within an exception, which may reduce pharmacy burden but could also raise concerns about oversight and diversion control.